Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists
Open Access
- 12 September 2014
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 10 (2) , 199-213
Abstract
Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors. Single-agent regorafenib administered as a 160-mg daily dose for the first 21 days of a 28-day cycle is approved for use in patients with pretreated metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumor (GIST) progressing on imatinib and sunitinib, following publication of data from the phase III CORRECT and GRID studies respectively. Regorafenib is currently under phase III investigation in patients with hepatocellular carcinoma and is in several phase II studies in patients with gastrointestinal (GI) tumors. This review describes the clinical development of regorafenib in patients with GI cancers, and highlights the key issues important for the modern day clinical pharmacist who forms part of the multidisciplinary team ensuring safe and effective delivery of the drug to the patient. This information is considered of particular importance to the clinical pharmacist for the future development of regorafenib in this treatment setting.Keywords
This publication has 31 references indexed in Scilit:
- Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer ModelMolecular Cancer Therapeutics, 2013
- In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).Journal of Clinical Oncology, 2013
- Role of targeted agents in metastatic colorectal cancerTargeted Oncology, 2013
- Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancersWorld Journal of Gastroenterology, 2013
- Role of oncology clinical pharmacist: a case of life-saving interventionsInternational Journal of Basic & Clinical Pharmacology, 2013
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingAnnals of Oncology, 2012
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Role of Oncology Clinical Pharmacists in Light of the Oncology Workforce StudyJournal of Oncology Practice, 2010
- Targeting Multiple Kinase Pathways: A Change In ParadigmClinical Cancer Research, 2010
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004